Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova, Italy.
Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Oncologist. 2022 Mar 4;27(2):e199-e202. doi: 10.1093/oncolo/oyab047.
Data on tumor immune-milieu after chemo-radiation (CT-RT) are scarce. Noninvasive tools are needed to improve the treatment of non-small cell lung cancer (NSCLC), especially in the locally advanced (LA) setting.
We collected a series of superior-sulcus (SS)- patients with NSCLC referred to our Institute (2015-2019), eligible for a preoperative CT-RT. We characterized tumor-infiltrating immune cells (TIICs), determined PD-L1-TPS and the residual viable tumor cells (RVTC). Radiological and metabolic responses were reviewed. We calculated pre-surgery neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR).
Eight patients were included. Radiological responses were 6 disease stabilities (SD) and 2 partial responses (PR). Metabolic responses were 4 SD and 4 PR. CD68+-TIICs were correlated with metabolic response and lower RVTC. CD68+-TIICs were associated with higher PLR. Higher PLR values seemed linked with lower RVTC.
These preliminary results could be useful for consolidation treatment selection for patients with LA-NSCLC without evaluable baseline PD-L1 and higher PLR values.
关于化疗放疗（CT-RT）后肿瘤免疫微环境的数据很少。需要非侵入性工具来改善非小细胞肺癌（NSCLC）的治疗，特别是在局部晚期（LA）环境中。
我们收集了一系列被转诊到我们研究所的位于上叶（SS）的 NSCLC 患者（2015-2019 年），这些患者有资格进行术前 CT-RT。我们对肿瘤浸润免疫细胞（TIICs）进行了特征描述，确定了 PD-L1-TPS 和残留存活肿瘤细胞（RVTC）。回顾了影像学和代谢反应。我们计算了术前中性粒细胞与淋巴细胞比值（NLR）和血小板与淋巴细胞比值（PLR）。
共纳入 8 例患者。影像学反应为 6 例疾病稳定（SD）和 2 例部分缓解（PR）。代谢反应为 4 例 SD 和 4 例 PR。CD68+ - TIICs 与代谢反应和较低的 RVTC 相关。CD68+ - TIICs 与较高的 PLR 相关。较高的 PLR 值似乎与较低的 RVTC 有关。
这些初步结果可能对无基线可评估 PD-L1 和较高 PLR 值的 LA-NSCLC 患者的巩固治疗选择有用。
